Clinical trials: Dermatitis Eczema
Dermatitis, Atopic
A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this research study is to investigate if KY1005 results in improvement of eczema when given to participants with moderate to severe disease. Side effects of KY1005 will also be explored.
- Trial name
- NCT03754309
- Testing
- KY1005
- Where
- 19 sites in Germany, Poland and 2 more
- Volunteers
- 89 people
- Sponsor
- Kymab Limited
Atopic Dermatitis (AD)
MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis
This is a Phase I/II Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT07182864
- Testing
- MH004 0.1% Ointment, MH004 0.3% Ointment, MH004 1.0% Ointment
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Atopic Dermatitis
Evaluation of the Efficacy of a Dermocosmetic Product RT00401-GO0046 on Atopic Dermititis Severity in Subjects With Mild Atopic Dermatitis Versus Placebo
The aim of this study is to evaluate the RT00401- GO0046 formula on atopic dermititis severity in subjects with mild atopic dermatitis versus placebo on 26 subjects.
- Trial name
- NCT06763939
- Testing
- RT00401-GO0046, RT00401-GA0677
- Where
- Poland
- Volunteers
- 32 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Mild to Moderate Atopic Dermatitis
Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
Elidel® is indicated for the short-term treatment and long-term management of signs and symptoms of atopic dermatitis (AD) in infants (3 to 23 months), children (2 to 11 years), adolescents (12 to 17 years), and adults.
- Trial name
- Elidel-SEA (NCT06052995)
- Testing
- Elidel 1% Topical Cream
- Where
- 9 sites in Malaysia, Taiwan and 1 more
- Volunteers
- 130 people
- Sponsor
- BGP Products Operations GmbH, a Viatris company
Atopic Dermatitis
Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product…
- Trial name
- NCT02896101
- Testing
- Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream
- Where
- 27 sites in United States
- Volunteers
- 755 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Cow Milk Allergy
Symptoms Based Awareness Confirmation Study - CoMiSS Validation
The Cow's Milk-related Symptom Score (CoMiSS) tool has been developed to define a score to recognize cow's milk related symptoms in infants and young children.
- Trial name
- MOSAIC (NCT03004729)
- Testing
- CoMiSS questionnaire
- Where
- 10 sites in China
- Volunteers
- 300 people
- Sponsor
- Société des Produits Nestlé (SPN)
Atopic Dermatitis
Comparison of LimpiAD Cream 2.5% Plus Versus Vehicle and an Emollient in Patients With Atopic Dermatitis
The purpose of this randomized clinical trial is to assess the efficacy and tolerability of LimpiAD, a medical device in the form of a 2.5% Plus cream, as compared to the Vehicle of LimpiAD 2.5% Plus cream and a standard…
- Trial name
- NCT05971355
- Testing
- LimpiAD cream 2,5% plus, Vehicle, Emollient
- Where
- 5 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Aileens Pharma SRL
Dermatitis, Atopic
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04365387
- Testing
- Nemolizumab
- Where
- 64 sites in United States
- Volunteers
- 242 people
- Sponsor
- Galderma R&D
Healthy Volunteer, Atopic Dermatitis
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases.
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Trial name
- NCT04772885
- Testing
- KT-474
- Where
- 14 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.
Atopic Dermatitis (AD)
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500.
- Trial name
- NCT06810050
- Testing
- CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- CAGE Bio Inc.
Atopic Dermatitis
Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis
The objective of this pilot double-blind study was to evaluate the efficacy and the safety of Broncho-Vaxom 1 capsule (3.5 mg) per day for 9 months compared to placebo on the evolution of the disease in children suffering from…
- Trial name
- NCT03047954
- Testing
- Broncho-Vaxom
- Volunteers
- 179 people
- Sponsor
- Vifor Pharma
Atopic Dermatitis Eczema
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
This was a Phase 3, 4-week, double-blind study to assess the safety and efficacy of ARQ-151 cream compared to vehicle cream applied once daily (qd) for 4 weeks in children 2 to 5 years of age with atopic dermatitis (AD).
- Trial name
- NCT04845620
- Testing
- Roflumilast Cream 0.05%, Vehicle Cream
- Where
- 76 sites in United States, Canada
- Volunteers
- 652 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults
This is a randomized, placebo-controlled, and double-blind study to evaluate the safety and bridging PK profile of FB825 for single SC administration in healthy adults.
- Trial name
- NCT05952986
- Testing
- FB825 in intravenous route
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Oneness Biotech Co., Ltd.
Atopic Dermatitis
Long-term Observational Study to Evalution the Safety and Efficacy of FURESTEM-AD Inj.
Observational Study to Assess the Safety and Efficacy of FURESTEM-AD lnj. In moderate to Atopic Dermatitis
- Trial name
- NCT03458624
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis
A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT05265923
- Testing
- CM310
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
- Trial name
- NCT05509023
- Testing
- ADX-914
- Where
- 24 sites in United States
- Volunteers
- 102 people
- Sponsor
- Q32 Bio Inc.
Atopic Dermatitis
Study of CM310 in Adolescent Subjects With Atopic Dermatis
This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06495229
- Testing
- CM310
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate…
- Trial name
- NCT05859724
- Testing
- NM26-2198
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Yellow Jersey Therapeutics AG
Healthy, Atopic Dermatitis
A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis
The clinical study consists of three parts: Part 1 with healthy volunteers. Part 2 and Part 3 including subjects with moderate to severe atopic dermatitis (a skin disease).
- Trial name
- NCT03689829
- Testing
- MOR106
- Where
- 15 sites in Germany, Spain and 2 more
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Atopic Dermatitis, Eczema
Clinical-Instrumental Study To Evaluate And Compare The Efficacy And Tolerability Of Two Emollients Products In Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with erythema, scaly and oozing plaques, and severe pruritus which has an important impact on quality of life and quality of sleep.
- Trial name
- NCT06930365
- Testing
- Anti-itching and repairing treatment. Emollient., Emollient cream
- Where
- Georgia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- NAOS Les Laboratoires
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.